{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T02:31:32Z","timestamp":1788489092643,"version":"build-2803163510"},"reference-count":128,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Published research suggests that patient-reported outcomes (PROs) are neither commonly collected nor reported in randomized clinical trials (RCTs) for solid tumors. Little is known about these practices in RCTs for hematological malignant neoplasms.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To evaluate the prevalence of PROs as prespecified end points in RCTs of hematological malignant neoplasms, and to assess reporting of PROs in associated trial publications.<\/jats:p>\n <\/jats:sec>\n \n Evidence Review<\/jats:title>\n \n All issues of 8 journals known for publishing high-impact RCTs (\n NEJM, Lancet, Lancet Hematology, Lancet Oncology, Journal of Clinical Oncology, Blood, JAMA, and JAMA Oncology<\/jats:italic>\n ) between January 1, 2018, and December 13, 2022, were searched for primary publications of therapeutic phase 3 trials for adults with hematological malignant neoplasms. Studies that evaluated pretransplant conditioning regimens, graft-vs-host disease treatment, or radiotherapy as experimental treatment were excluded. Data regarding trial characteristics and PROs were extracted from manuscripts and trial protocols. Univariable analyses assessed associations between trial characteristics and PRO collection or reporting.\n <\/jats:p>\n <\/jats:sec>\n \n Findings<\/jats:title>\n \n Ninety RCTs were eligible for analysis. PROs were an end point in 66 (73%) trials: in 1 trial (1%) as a primary end point, in 50 (56%) as a secondary end point, and in 15 (17%) as an exploratory end point. PRO data were reported in 26 of 66 primary publications (39%): outcomes were unchanged in 18 and improved in 8, with none reporting worse PROs with experimental treatment. Trials sponsored by for-profit entities were more likely to include PROs as an end point (49 of 55 [89%] vs 17 of 35 [49%];\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001) but were not significantly more likely to report PRO data (20 of 49 [41%] vs 6 of 17 [35%];\n P<\/jats:italic>\n \u2009=\u2009.69). Compared with trials involving lymphoma (18 of 29 [62%]) or leukemia or myelodysplastic syndrome (18 of 28 [64%]), those involving plasma cell disorders or multiple myeloma (27 of 30 [90%]) or myeloproliferative neoplasms (3 of 3 [100%]) were more likely to include PROs as an end point (\n P<\/jats:italic>\n \u2009=\u2009.03). Similarly, compared with trials involving lymphoma (3 of 18 [17%]) or leukemia or myelodysplastic syndrome (5 of 18 [28%]), those involving plasma cell disorders or multiple myeloma (16 of 27 [59%]) or myeloproliferative neoplasms (2 of 3 [67%]) were more likely to report PROs in the primary publication (\n P<\/jats:italic>\n \u2009=\u2009.01).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this systematic review, almost 3 of every 4 therapeutic RCTs for blood cancers collected PRO data; however, only 1 RCT included PROs as a primary end point. Moreover, most did not report resulting PRO data in the primary publication and when reported, PROs were either better or unchanged, raising concern for publication bias. This analysis suggests a critical gap in dissemination of data on the lived experiences of patients enrolled in RCTs for hematological malignant neoplasms.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2024.14425","type":"journal-article","created":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T11:16:41Z","timestamp":1717413401000},"page":"e2414425","source":"Crossref","is-referenced-by-count":21,"title":["Patient-Reported Outcomes in Phase 3 Clinical Trials for Blood Cancers: A Systematic Review"],"prefix":"10.1001","volume":"7","author":[{"given":"Kishan","family":"Patel","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Brigham & Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Ivanov","sequence":"additional","affiliation":[{"name":"Division of Population Sciences, Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tajmah","family":"Jocelyn","sequence":"additional","affiliation":[{"name":"Center for Clinical Investigation, Brigham & Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Hantel","sequence":"additional","affiliation":[{"name":"Division of Population Sciences, Dana-Farber Cancer Institute, Boston, Massachusetts"},{"name":"Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline S.","family":"Garcia","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory A.","family":"Abel","sequence":"additional","affiliation":[{"name":"Division of Population Sciences, Dana-Farber Cancer Institute, Boston, Massachusetts"},{"name":"Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2024,6,3]]},"reference":[{"issue":"32","key":"zoi240493r1","doi-asserted-by":"publisher","first-page":"5121","DOI":"10.1200\/JCO.2007.12.4784","article-title":"Patient-reported outcomes and the evolution of adverse event reporting in oncology.","volume":"25","author":"Trotti","year":"2007","journal-title":"J Clin Oncol"},{"issue":"10","key":"zoi240493r2","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1056\/NEJMp0911494","article-title":"The missing voice of patients in drug-safety reporting.","volume":"362","author":"Basch","year":"2010","journal-title":"N Engl J Med"},{"issue":"17","key":"zoi240493r3","doi-asserted-by":"publisher","first-page":"3485","DOI":"10.1200\/JCO.2004.03.025","article-title":"How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30.","volume":"22","author":"Fromme","year":"2004","journal-title":"J Clin Oncol"},{"issue":"8","key":"zoi240493r4","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1200\/JCO.2014.57.9334","article-title":"Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials.","volume":"33","author":"Di Maio","year":"2015","journal-title":"J Clin Oncol"},{"issue":"5","key":"zoi240493r5","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/nrclinonc.2015.222","article-title":"Patient-reported outcomes in the evaluation of toxicity of anticancer treatments.","volume":"13","author":"Di Maio","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"issue":"11","key":"zoi240493r6","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/S1470-2045(06)70910-X","article-title":"Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study.","volume":"7","author":"Basch","year":"2006","journal-title":"Lancet Oncol"},{"issue":"8","key":"zoi240493r7","doi-asserted-by":"publisher","first-page":"3669","DOI":"10.1007\/s00520-016-3297-9","article-title":"The association between clinician-based common terminology criteria for adverse events (CTCAE) and patient-reported outcomes (PRO): a systematic review.","volume":"24","author":"Atkinson","year":"2016","journal-title":"Support Care Cancer"},{"issue":"8","key":"zoi240493r8","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1093\/jnci\/djab015","article-title":"Underreporting of symptomatic adverse events in phase i clinical trials.","volume":"113","author":"Veitch","year":"2021","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"zoi240493r9","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/jog.v50.1","article-title":"Prospective analysis of patient-reported outcomes and physician-reported outcomes with gynecologic cancer chemotherapy.","volume":"50","author":"Takenaga","year":"2024","journal-title":"J Obstet Gynaecol Res"},{"issue":"23","key":"zoi240493r10","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1093\/jnci\/djp386","article-title":"Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes.","volume":"101","author":"Basch","year":"2009","journal-title":"J Natl Cancer Inst"},{"issue":"23","key":"zoi240493r11","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1200\/JCO.2015.61.6706","article-title":"American Society of Clinical Oncology Statement: a conceptual framework to assess the value of cancer treatment options.","volume":"33","author":"Schnipper","year":"2015","journal-title":"J Clin Oncol"},{"issue":"8","key":"zoi240493r12","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1093\/annonc\/mdv249","article-title":"A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS).","volume":"26","author":"Cherny","year":"2015","journal-title":"Ann Oncol"},{"issue":"1","key":"zoi240493r13","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1093\/annonc\/mdu489","article-title":"Poor patient-reported outcomes reporting according to CONSORT guidelines in randomized clinical trials evaluating systemic cancer therapy.","volume":"26","author":"Bylicki","year":"2015","journal-title":"Ann Oncol"},{"issue":"12","key":"zoi240493r14","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1093\/annonc\/mdy449","article-title":"Deficiencies in health-related quality-of-life assessment and reporting: a systematic review of oncology randomized phase 3 trials published between 2012 and 2016.","volume":"29","author":"Marandino","year":"2018","journal-title":"Ann Oncol"},{"issue":"10","key":"zoi240493r15","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1093\/annonc\/mdx354","article-title":"Changes in the use of end points in clinical trials for elderly cancer patients over time.","volume":"28","author":"Le Saux","year":"2017","journal-title":"Ann Oncol"},{"issue":"3","key":"zoi240493r16","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.0363","article-title":"Patient experience captured by quality-of-life measurement in oncology clinical trials.","volume":"3","author":"Haslam","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"22","key":"zoi240493r17","doi-asserted-by":"publisher","first-page":"4630","DOI":"10.1182\/bloodadvances.2021004190","article-title":"Assessment and reporting of quality-of-life measures in pivotal clinical trials of hematological malignancies.","volume":"5","author":"Al Hadidi","year":"2021","journal-title":"Blood Adv"},{"issue":"34","key":"zoi240493r19","doi-asserted-by":"publisher","first-page":"3361","DOI":"10.1200\/JCO.2018.78.8414","article-title":"Hydroxycarbamide plus aspirin versus aspirin alone in patients with essential thrombocythemia age 40 to 59 years without high-risk features.","volume":"36","author":"Godfrey","year":"2018","journal-title":"J Clin Oncol"},{"issue":"19","key":"zoi240493r20","doi-asserted-by":"publisher","first-page":"2931","DOI":"10.1182\/blood.2021012743","article-title":"A randomized phase 3 trial of interferon-a vs hydroxyurea in polycythemia vera and essential thrombocythemia.","volume":"139","author":"Mascarenhas","year":"2022","journal-title":"Blood"},{"issue":"5","key":"zoi240493r21","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1001\/jamaoncol.2017.5818","article-title":"Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis: a randomized clinical trial.","volume":"4","author":"Mascarenhas","year":"2018","journal-title":"JAMA Oncol"},{"issue":"1","key":"zoi240493r22","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1056\/NEJMoa2028631","article-title":"Daratumumab-based treatment for immunoglobulin light-chain amyloidosis.","volume":"385","author":"Kastritis","year":"2021","journal-title":"NEJM"},{"issue":"28","key":"zoi240493r23","doi-asserted-by":"publisher","first-page":"3252","DOI":"10.1200\/JCO.20.01285","article-title":"Bortezomib, melphalan, and dexamethasone for light-chain amyloidosis.","volume":"38","author":"Kastritis","year":"2020","journal-title":"J Clin Oncol"},{"issue":"2","key":"zoi240493r24","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMoa2204925","article-title":"Triplet therapy, transplantation, and maintenance until progression in myeloma.","volume":"387","author":"Richardson","year":"2022","journal-title":"NEJM"},{"issue":"22","key":"zoi240493r25","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus lenalidomide and dexamethasone for untreated myeloma.","volume":"380","author":"Facon","year":"2019","journal-title":"NEJM"},{"issue":"6","key":"zoi240493r26","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma.","volume":"378","author":"Mateos","year":"2018","journal-title":"NEJM"},{"issue":"10292","key":"zoi240493r27","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1016\/S0140-6736(21)00592-4","article-title":"Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial.","volume":"397","author":"Moreau","year":"2021","journal-title":"Lancet"},{"issue":"10262","key":"zoi240493r28","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/S0140-6736(20)32292-3","article-title":"Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial.","volume":"396","author":"Grosicki","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"zoi240493r29","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S1470-2045(21)00579-9","article-title":"Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study.","volume":"23","author":"Usmani","year":"2022","journal-title":"Lancet Oncol"},{"issue":"10214","key":"zoi240493r30","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1016\/S0140-6736(19)32556-5","article-title":"Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.","volume":"394","author":"Attal","year":"2019","journal-title":"Lancet"},{"issue":"10168","key":"zoi240493r31","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/S0140-6736(18)33003-4","article-title":"Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINEMM3): a double-blind, randomised, placebo-controlled phase 3 trial.","volume":"393","author":"Dimopoulos","year":"2019","journal-title":"Lancet"},{"issue":"6","key":"zoi240493r32","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/S1470-2045(21)00128-5","article-title":"Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial.","volume":"22","author":"Dimopoulos","year":"2021","journal-title":"Lancet Oncol"},{"issue":"12","key":"zoi240493r33","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1016\/S1470-2045(20)30525-8","article-title":"Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial.","volume":"21","author":"Kumar","year":"2020","journal-title":"Lancet Oncol"},{"issue":"10","key":"zoi240493r34","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1016\/S1470-2045(20)30452-6","article-title":"Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stemcell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial.","volume":"21","author":"Kumar","year":"2020","journal-title":"Lancet Oncol"},{"issue":"6","key":"zoi240493r35","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/S1470-2045(19)30152-4","article-title":"Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, openlabel, phase 3 trial.","volume":"20","author":"Richardson","year":"2019","journal-title":"Lancet Oncol"},{"issue":"1","key":"zoi240493r36","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S1470-2045(18)30687-9","article-title":"Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial.","volume":"20","author":"Jackson","year":"2019","journal-title":"Lancet Oncol"},{"issue":"7","key":"zoi240493r37","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/S1470-2045(18)30354-1","article-title":"Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study.","volume":"19","author":"Moreau","year":"2018","journal-title":"Lancet Oncol"},{"issue":"11","key":"zoi240493r38","doi-asserted-by":"publisher","first-page":"e810","DOI":"10.1016\/S2352-3026(22)00263-0","article-title":"Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial.","volume":"9","author":"Goldschmidt","year":"2022","journal-title":"Lancet Haematol"},{"issue":"6","key":"zoi240493r39","doi-asserted-by":"publisher","first-page":"e403","DOI":"10.1016\/S2352-3026(22)00103-X","article-title":"Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial.","volume":"9","author":"Dimopoulos","year":"2022","journal-title":"Lancet Haematol"},{"issue":"2","key":"zoi240493r40","doi-asserted-by":"publisher","first-page":"e98","DOI":"10.1016\/S2352-3026(21)00381-1","article-title":"Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study.","volume":"9","author":"Schjesvold","year":"2022","journal-title":"Lancet Haematol"},{"issue":"5","key":"zoi240493r41","doi-asserted-by":"publisher","first-page":"e370","DOI":"10.1016\/S2352-3026(20)30070-3","article-title":"Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial.","volume":"7","author":"Mateos","year":"2020","journal-title":"Lancet Haematol"},{"issue":"12","key":"zoi240493r42","doi-asserted-by":"publisher","first-page":"e616","DOI":"10.1016\/S2352-3026(19)30167-X","article-title":"Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial.","volume":"6","author":"Jackson","year":"2019","journal-title":"Lancet Haematol"},{"issue":"9","key":"zoi240493r43","doi-asserted-by":"publisher","first-page":"e448","DOI":"10.1016\/S2352-3026(19)30109-7","article-title":"Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-na\u00efve multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial.","volume":"6","author":"Usmani","year":"2019","journal-title":"Lancet Haematol"},{"issue":"9","key":"zoi240493r44","doi-asserted-by":"publisher","first-page":"e459","DOI":"10.1016\/S2352-3026(19)30110-3","article-title":"Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial.","volume":"6","author":"Mateos","year":"2019","journal-title":"Lancet Haematol"},{"issue":"34","key":"zoi240493r45","doi-asserted-by":"publisher","first-page":"4030","DOI":"10.1200\/JCO.20.02060","article-title":"Ixazomib as postinduction maintenance for patients with newly diagnosed multiple myeloma not undergoing autologous stem cell transplantation: the phase III TOURMALINE-MM4 Trial.","volume":"38","author":"Dimopoulos","year":"2020","journal-title":"J Clin Oncol"},{"issue":"23","key":"zoi240493r46","doi-asserted-by":"publisher","first-page":"2647","DOI":"10.1200\/JCO.20.00298","article-title":"Randomized trial comparing double versus triple bortezomib-based regimen in patients with multiple myeloma and acute kidney injury due to cast nephropathy.","volume":"38","author":"Bridoux","year":"2020","journal-title":"J Clin Oncol"},{"issue":"7","key":"zoi240493r47","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1200\/JCO.18.00685","article-title":"Autologous transplantation, consolidation, and maintenance therapy in multiple myeloma: results of the BMT CTN 0702 Trial.","volume":"37","author":"Stadtmauer","year":"2019","journal-title":"J Clin Oncol"},{"issue":"26","key":"zoi240493r48","doi-asserted-by":"publisher","first-page":"3616","DOI":"10.1182\/blood.2020008787","article-title":"Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma.","volume":"137","author":"Facon","year":"2021","journal-title":"Blood"},{"issue":"11","key":"zoi240493r49","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1200\/JCO.19.01740","article-title":"Randomized trial of lenalidomide versus observation in smoldering multiple myeloma.","volume":"38","author":"Lonial","year":"2020","journal-title":"J Clin Oncol"},{"issue":"25","key":"zoi240493r50","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1056\/NEJMoa1802917","article-title":"Phase 3 trial of ibrutinib plus rituximab in Waldenstr\u00f6m\u2019s macroglobulinemia.","volume":"378","author":"Dimopoulos","year":"2018","journal-title":"NEJM"},{"issue":"18","key":"zoi240493r51","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1182\/blood.2020006844","article-title":"A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstr\u00f6m macroglobulinemia: the ASPEN study.","volume":"136","author":"Tam","year":"2020","journal-title":"Blood"},{"issue":"4","key":"zoi240493r52","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma.","volume":"386","author":"Tilly","year":"2022","journal-title":"NEJM"},{"issue":"10343","key":"zoi240493r53","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","article-title":"Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial.","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet"},{"issue":"5","key":"zoi240493r54","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/S1470-2045(18)30935-5","article-title":"Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial.","volume":"20","author":"Davies","year":"2019","journal-title":"Lancet Oncol"},{"issue":"12","key":"zoi240493r55","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1200\/JCO.20.01366","article-title":"ROBUST: a phase III study of lenalidomide plus R-CHOP versus placebo plus R-CHOP in previously untreated patients with ABC-type diffuse large B-cell lymphoma.","volume":"39","author":"Nowakowski","year":"2021","journal-title":"J Clin Oncol"},{"issue":"11","key":"zoi240493r56","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1200\/JCO.20.02666","article-title":"Subcutaneous rituximab-MiniCHOP compared with subcutaneous rituximab-MiniCHOP plus lenalidomide in diffuse large B-cell lymphoma for patients age 80 years or older.","volume":"39","author":"Oberic","year":"2021","journal-title":"J Clin Oncol"},{"issue":"29","key":"zoi240493r57","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.1200\/JCO.19.03418","article-title":"Rituximab-CHOP with early rituximab intensification for diffuse large B-cell lymphoma: a randomized phase III trial of the HOVON and the Nordic Lymphoma Group (HOVON-84).","volume":"38","author":"Lugtenburg","year":"2020","journal-title":"J Clin Oncol"},{"issue":"21","key":"zoi240493r58","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1200\/JCO.18.01994","article-title":"Dose-adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-cell lymphoma: clinical outcomes of the Phase III Intergroup Trial Alliance\/CALGB 50303.","volume":"37","author":"Bartlett","year":"2019","journal-title":"J Clin Oncol"},{"issue":"15","key":"zoi240493r59","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1200\/JCO.18.02403","article-title":"Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non\u2013germinal center B-cell diffuse large B-cell lymphoma.","volume":"37","author":"Younes","year":"2019","journal-title":"J Clin Oncol"},{"issue":"17","key":"zoi240493r60","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1182\/blood.2020008750","article-title":"Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSA.","volume":"137","author":"Le Gouill","year":"2021","journal-title":"Blood"},{"issue":"10","key":"zoi240493r61","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1056\/NEJMoa1805104","article-title":"Rituximab plus lenalidomide in advanced untreated follicular lymphoma.","volume":"379","author":"Morschhauser","year":"2018","journal-title":"NEJM"},{"issue":"11","key":"zoi240493r62","doi-asserted-by":"publisher","first-page":"e543","DOI":"10.1016\/S2352-3026(18)30157-1","article-title":"Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 in comparison with rituximab in patients with previously untreated low-tumour-burden follicular lymphoma: a randomised, double-blind, parallel-group, phase 3 trial.","volume":"5","author":"Ogura","year":"2018","journal-title":"Lancet Haematol"},{"issue":"7","key":"zoi240493r63","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1200\/JCO.21.01234","article-title":"Response-adapted postinduction strategy in patients with advanced-stage follicular lymphoma: the FOLL12 Study.","volume":"40","author":"Luminari","year":"2022","journal-title":"J Clin Oncol"},{"issue":"29","key":"zoi240493r64","doi-asserted-by":"publisher","first-page":"2918","DOI":"10.1200\/JCO.2018.77.9892","article-title":"Randomized trial of systemic therapy after involved-field radiotherapy in patients with early-stage follicular lymphoma: TROG 99.03.","volume":"36","author":"MacManus","year":"2018","journal-title":"J Clin Oncol"},{"issue":"4","key":"zoi240493r65","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin\u2019s lymphoma.","volume":"378","author":"Connors","year":"2018","journal-title":"NEJM"},{"issue":"4","key":"zoi240493r66","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/S1470-2045(21)00005-X","article-title":"Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study.","volume":"22","author":"Kuruvilla","year":"2021","journal-title":"Lancet Oncol"},{"issue":"2","key":"zoi240493r67","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/S1470-2045(18)30784-8","article-title":"PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study.","volume":"20","author":"Casasnovas","year":"2019","journal-title":"Lancet Oncol"},{"issue":"26","key":"zoi240493r68","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1056\/NEJMoa2201817","article-title":"Ibrutinib plus bendamustine and rituximab in untreated mantle-cell lymphoma.","volume":"386","author":"Wang","year":"2022","journal-title":"NEJM"},{"issue":"1","key":"zoi240493r69","doi-asserted-by":"publisher","first-page":"e34","DOI":"10.1016\/S2352-3026(20)30358-6","article-title":"Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation in mantle cell lymphoma: results of a Fondazione Italiana Linfomi (FIL) multicentre, randomised, phase 3 trial.","volume":"8","author":"Ladetto","year":"2021","journal-title":"Lancet Haematol"},{"issue":"20","key":"zoi240493r70","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1200\/JCO.2017.76.8093","article-title":"Positron Emission Tomography\u2013Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL): a multicenter, randomized phase III trial.","volume":"36","author":"D\u00fchrsen","year":"2018","journal-title":"J Clin Oncol"},{"issue":"7","key":"zoi240493r71","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1056\/NEJMoa2116596","article-title":"Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma.","volume":"386","author":"Bishop","year":"2022","journal-title":"NEJM"},{"issue":"7","key":"zoi240493r72","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma.","volume":"386","author":"Locke","year":"2022","journal-title":"NEJM"},{"issue":"10216","key":"zoi240493r73","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1016\/S0140-6736(19)33008-9","article-title":"Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial.","volume":"394","author":"Poeschel","year":"2019","journal-title":"Lancet"},{"issue":"5","key":"zoi240493r74","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/S1470-2045(21)00145-5","article-title":"Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial.","volume":"22","author":"Matasar","year":"2021","journal-title":"Lancet Oncol"},{"issue":"14","key":"zoi240493r75","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1200\/JCO.19.00010","article-title":"AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma.","volume":"37","author":"Leonard","year":"2019","journal-title":"J Clin Oncol"},{"issue":"2","key":"zoi240493r76","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/S1470-2045(18)30747-2","article-title":"Rituximab in patients with primary CNS lymphoma (HOVON 105\/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study.","volume":"20","author":"Bromberg","year":"2019","journal-title":"Lancet Oncol"},{"issue":"9","key":"zoi240493r77","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/S1470-2045(18)30379-6","article-title":"Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.","volume":"19","author":"Kim","year":"2018","journal-title":"Lancet Oncol"},{"issue":"10168","key":"zoi240493r78","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial.","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet"},{"issue":"3","key":"zoi240493r79","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1200\/JCO.21.01815","article-title":"Romidepsin plus CHOP versus CHOP in patients with previously untreated peripheral T-cell lymphoma: results of the Ro-CHOP phase III study (conducted by LYSA).","volume":"40","author":"Bachy","year":"2022","journal-title":"J Clin Oncol"},{"issue":"8","key":"zoi240493r80","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1200\/JCO.18.00899","article-title":"Randomized phase III study of alisertib or investigator\u2019s choice (selected single agent) in patients with relapsed or refractory peripheral T-cell lymphoma.","volume":"37","author":"O\u2019Connor","year":"2019","journal-title":"J Clin Oncol"},{"issue":"4","key":"zoi240493r81","doi-asserted-by":"publisher","first-page":"e262","DOI":"10.1016\/S2352-3026(22)00038-2","article-title":"Addition of four doses of rituximab to standard induction chemotherapy in adult patients with precursor B-cell acute lymphoblastic leukaemia (UKALL14): a phase 3, multicentre, randomised controlled trial.","volume":"9","author":"Marks","year":"2022","journal-title":"Lancet Haematol"},{"issue":"24","key":"zoi240493r82","doi-asserted-by":"publisher","first-page":"2514","DOI":"10.1200\/JCO.2017.76.8192","article-title":"Intensified therapy of acute lymphoblastic leukemia in adults: report of the Randomized GRAALL-2005 clinical trial.","volume":"36","author":"Huguet","year":"2018","journal-title":"J Clin Oncol"},{"issue":"16","key":"zoi240493r83","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1056\/NEJMoa2117344","article-title":"Ivosidenib and azacitidine in IDH1-mutated acute myeloid leukemia.","volume":"386","author":"Montesinos","year":"2022","journal-title":"NEJM"},{"issue":"26","key":"zoi240493r84","doi-asserted-by":"publisher","first-page":"2526","DOI":"10.1056\/NEJMoa2004444","article-title":"Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission.","volume":"383","author":"Wei","year":"2020","journal-title":"NEJM"},{"issue":"7","key":"zoi240493r85","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia.","volume":"383","author":"DiNardo","year":"2020","journal-title":"NEJM"},{"issue":"18","key":"zoi240493r86","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","article-title":"Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML.","volume":"381","author":"Perl","year":"2019","journal-title":"NEJM"},{"issue":"9","key":"zoi240493r87","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1016\/S1470-2045(20)30455-1","article-title":"Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomized phase 3 trial.","volume":"21","author":"Xuan","year":"2020","journal-title":"Lancet Oncol"},{"issue":"7","key":"zoi240493r88","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/S1470-2045(19)30150-0","article-title":"Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial.","volume":"20","author":"Cortes","year":"2019","journal-title":"Lancet Oncol"},{"issue":"6","key":"zoi240493r89","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1200\/JCO.19.01406","article-title":"Gemtuzumab ozogamicin in NPM1-mutated acute myeloid leukemia: early results from the prospective randomized AMLSG 09-09 phase III study.","volume":"38","author":"Schlenk","year":"2020","journal-title":"J Clin Oncol"},{"issue":"26","key":"zoi240493r90","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1200\/JCO.2017.77.6112","article-title":"CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia.","volume":"36","author":"Lancet","year":"2018","journal-title":"J Clin Oncol"},{"issue":"24","key":"zoi240493r91","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1182\/blood.2020004856","article-title":"Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial.","volume":"135","author":"Wei","year":"2020","journal-title":"Blood"},{"issue":"13","key":"zoi240493r92","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1182\/blood-2018-10-879866","article-title":"Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients.","volume":"133","author":"Huls","year":"2019","journal-title":"Blood"},{"issue":"7","key":"zoi240493r93","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/S1470-2045(18)30295-X","article-title":"Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial.","volume":"19","author":"Zhu","year":"2018","journal-title":"Lancet Oncol"},{"issue":"5","key":"zoi240493r94","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1056\/NEJMoa1817073","article-title":"Ibrutinib\u2013rituximab or chemoimmunotherapy for chronic lymphocytic leukemia.","volume":"381","author":"Shanafelt","year":"2019","journal-title":"NEJM"},{"issue":"23","key":"zoi240493r95","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","article-title":"Venetoclax and obinutuzumab in patients with CLL and coexisting conditions.","volume":"380","author":"Fischer","year":"2019","journal-title":"NEJM"},{"issue":"26","key":"zoi240493r96","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","article-title":"Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL.","volume":"379","author":"Woyach","year":"2018","journal-title":"NEJM"},{"issue":"12","key":"zoi240493r97","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","article-title":"Venetoclax\u2013rituximab in relapsed or refractory chronic lymphocytic leukemia.","volume":"378","author":"Seymour","year":"2018","journal-title":"NEJM"},{"issue":"8","key":"zoi240493r98","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/S1470-2045(22)00293-5","article-title":"Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial.","volume":"23","author":"Tam","year":"2022","journal-title":"Lancet Oncol"},{"issue":"1","key":"zoi240493r99","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S1470-2045(18)30788-5","article-title":"Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial.","volume":"20","author":"Moreno","year":"2019","journal-title":"Lancet Oncol"},{"issue":"4","key":"zoi240493r100","doi-asserted-by":"publisher","first-page":"e254","DOI":"10.1016\/S2352-3026(20)30433-6","article-title":"Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial.","volume":"8","author":"Sharman","year":"2021","journal-title":"Lancet Haematol"},{"issue":"31","key":"zoi240493r101","doi-asserted-by":"publisher","first-page":"3441","DOI":"10.1200\/JCO.21.01210","article-title":"Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial.","volume":"39","author":"Byrd","year":"2021","journal-title":"J Clin Oncol"},{"issue":"25","key":"zoi240493r102","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1200\/JCO.19.03355","article-title":"ASCEND: phase III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia.","volume":"38","author":"Ghia","year":"2020","journal-title":"J Clin Oncol"},{"issue":"23","key":"zoi240493r103","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1182\/blood-2018-05-850461","article-title":"The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL\/SLL.","volume":"132","author":"Flinn","year":"2018","journal-title":"Blood"},{"issue":"3","key":"zoi240493r104","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1200\/JCO.2017.74.7162","article-title":"Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial.","volume":"36","author":"Cortes","year":"2018","journal-title":"J Clin Oncol"},{"issue":"21","key":"zoi240493r105","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1182\/blood.2020009984","article-title":"A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs.","volume":"138","author":"R\u00e9a","year":"2021","journal-title":"Blood"},{"issue":"2","key":"zoi240493r106","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1056\/NEJMoa1908892","article-title":"Luspatercept in patients with lower-risk myelodysplastic syndromes.","volume":"382","author":"Fenaux","year":"2020","journal-title":"NEJM"},{"issue":"13","key":"zoi240493r107","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1200\/JCO.20.02619","article-title":"Phase III, randomized, placebo-controlled trial of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes.","volume":"39","author":"Garcia-Manero","year":"2021","journal-title":"J Clin Oncol"},{"issue":"9","key":"zoi240493r108","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1200\/JCO.20.01691","article-title":"Lenalidomide-epoetin alfa versus lenalidomide monotherapy in myelodysplastic syndromes refractory to recombinant erythropoietin.","volume":"39","author":"List","year":"2021","journal-title":"J Clin Oncol"},{"issue":"35","key":"zoi240493r121","doi-asserted-by":"publisher","first-page":"4095","DOI":"10.1200\/JCO.22.00535","article-title":"Overall survival, progression-free survival, and tumor response benefit supporting initial US Food and Drug Administration approval and indication extension of new cancer drugs, 2003-2021.","volume":"40","author":"Michaeli","year":"2022","journal-title":"J Clin Oncol"},{"key":"zoi240493r122","doi-asserted-by":"publisher","first-page":"j4530","DOI":"10.1136\/bmj.j4530","article-title":"Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13.","volume":"359","author":"Davis","year":"2017","journal-title":"BMJ"},{"issue":"6","key":"zoi240493r123","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1001\/jamaoncol.2022.0864","article-title":"Association of quality-of-life outcomes in cancer drug trials with survival outcomes and drug class.","volume":"8","author":"Samuel","year":"2022","journal-title":"JAMA Oncol"},{"key":"zoi240493r124","doi-asserted-by":"publisher","first-page":"k4383","DOI":"10.1136\/bmj.k4383","article-title":"Reporting harms more transparently in trials of cancer drugs.","volume":"363","author":"Gyawali","year":"2018","journal-title":"BMJ"},{"issue":"8","key":"zoi240493r125","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1001\/jama.2013.879","article-title":"Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension.","volume":"309","author":"Calvert","year":"2013","journal-title":"JAMA"},{"issue":"5","key":"zoi240493r126","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1001\/jama.2017.21903","article-title":"Guidelines for inclusion of patient-reported outcomes in clinical trial protocols: the SPIRIT-PRO Extension.","volume":"319","author":"Calvert","year":"2018","journal-title":"JAMA"},{"issue":"1","key":"zoi240493r127","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1093\/jnci\/djab087","article-title":"Patient-reported outcomes in pediatric cancer registration trials: a US Food and Drug Administration perspective.","volume":"114","author":"Murugappan","year":"2022","journal-title":"J Natl Cancer Inst"},{"key":"zoi240493r128","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ejca.2021.04.023","article-title":"Rare use of patient-reported outcomes in childhood cancer clinical trials\u2014a systematic review of clinical trial registries.","volume":"152","author":"Riedl","year":"2021","journal-title":"Eur J Cancer"},{"key":"zoi240493r18","unstructured":"The Centre for Evidence-Based Medicine. Oxford Center for Evidence-based Medicine\u2019s Levels of Evidence and Grades of Recommendation. Accessed June 17, 2023. https:\/\/www.cebm.net"},{"key":"zoi240493r109","unstructured":"European Organisation for Research and Treatment of Cancer. EORTC Questionnaires. Accessed December 1, 2023. https:\/\/qol.eortc.org\/questionnaires\/"},{"key":"zoi240493r110","unstructured":"EuroQOL. EQ-5D-3L information page. Accessed December 1, 2023. https:\/\/euroqol.org\/information-and-support\/euroqol-instruments\/eq-5d-3l\/"},{"key":"zoi240493r111","unstructured":"FACIT Group. FACT Measures. Accessed December 1, 2023. https:\/\/www.facit.org\/facit-measures-searchable-library"},{"key":"zoi240493r112","unstructured":"RAND Corporation. 36-Item Short Form Survey (SF-36). Accessed December 1, 2023. https:\/\/www.rand.org\/health-care\/surveys_tools\/mos\/36-item-short-form.html"},{"key":"zoi240493r113","unstructured":"PROMIS Health Organization. Accessed December 1, 2023. https:\/\/www.promishealth.org\/57461-2\/"},{"key":"zoi240493r114","unstructured":"University of Texas MD Anderson Cancer Center. The MD Anderson Symptom Inventory. Accessed December 1, 2023. https:\/\/www.mdanderson.org\/research\/departments-labs-institutes\/departments-divisions\/symptom-research\/symptom-assessment-tools\/md-anderson-symptom-inventory.html"},{"key":"zoi240493r115","unstructured":"USAID. Accessed December 1, 2023. https:\/\/www.advancingnutrition.org\/resources\/caregiver-toolkit\/mental-health\/general-health-questionnaire-ghq-12"},{"key":"zoi240493r116","unstructured":"IQVIA. Treatment Satisfaction Questionnaire for Medication (TSQM). Accessed December 1, 2023. https:\/\/www.iqvia.com\/library\/fact-sheets\/treatment-satisfaction-questionnaire-for-medication-tsqm"},{"key":"zoi240493r117","unstructured":"National Institute of Mental Health. Patient Global Impressions scale\u2014Change, Improvement, Severity (PGI-C, PGI-I, PGI-S). Accessed December 1, 2023. https:\/\/eprovide.mapi-trust.org\/instruments\/patient-global-impressions-scale-change-improvement-severity"},{"key":"zoi240493r118","unstructured":"Reilly Associates. Accessed December 1, 2023. http:\/\/www.reillyassociates.net"},{"key":"zoi240493r119","unstructured":"University of Texas MD Anderson Cancer Center. Brief Pain Inventory. Accessed December 1, 2023. https:\/\/www.mdanderson.org\/research\/departments-labs-institutes\/departments-divisions\/symptom-research\/symptom-assessment-tools\/brief-pain-inventory.html"},{"key":"zoi240493r120","unstructured":"Emory University. Itchy QoL: A Pruritus-Specific Quality of Life Instrument. March 26, 2009. Accessed December 1, 2023. https:\/\/emoryott.technologypublisher.com\/tech?title=ItchyQol%3a_A_Pruritus-Specific_Quality_of_Life_Instrument"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2819399\/patel_2024_oi_240493_1716496102.02829.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T11:16:51Z","timestamp":1717413411000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2819399"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,3]]},"references-count":128,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.14425","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,3]]}}}